2022
Intratumour heterogeneity, from hypothesis to the clinic
Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.Commentaries, Editorials and Letters
2009
Secreted Frizzled Receptor Protein 1 (sFRP-1) as Both a Potential Novel Biomarker of Triple Negative Breast Cancer (TNBC), and Its Sensitivity Against Taxane/Anthracycline Containing Neoadjuvant Chemotherapy.
Liedtke C, Ruckert C, Goette M, von Wahlde M, Kiesel L, Symmans W, Pusztai L. Secreted Frizzled Receptor Protein 1 (sFRP-1) as Both a Potential Novel Biomarker of Triple Negative Breast Cancer (TNBC), and Its Sensitivity Against Taxane/Anthracycline Containing Neoadjuvant Chemotherapy. Cancer Research 2009, 69: 4047-4047. DOI: 10.1158/0008-5472.sabcs-09-4047.Peer-Reviewed Original ResearchTriple-negative breast cancerRelapse-free survivalNegative breast cancerNeoadjuvant chemotherapyBreast cancerKi67 expressionTriple-negative breast cancer (TNBC) phenotypeNovel markerProtein 1Breast cancer phenotypeExpression of Ki67Breast cancer subtypesSFRP-1Breast cancer cell linesMDA-MB-468 breast cancer cell linePotential novel biomarkersCell linesSFRP-1 expressionNegative cell linesAnthracycline chemotherapyCancer cell linesFree survivalSystemic therapyUnfavorable prognosisNovel biomarkers